Saturday, October 31, 2026

CBOE Went Down By Over 27% In The Last 21 Sessions

CBOE Went Down By Over 27% In The Last 21 Sessions

(VIANEWS) - CBOE (VIX) has been up by 27.45% for the last 21 sessions. At 04:08 EST on Wednesday, 12 April, CBOE (VIX) is $19.24.

About CBOE's yearly highs and lows, it's 12.78% up from its 52-week low and 47.49% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a positive 0.03%, a negative 1.23%, and a positive 4.82%, respectively.

CBOE's highest amplitude of average volatility was 2.50% (last week), 4.68% (last month), and 4.82% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CBOE's is considered to be oversold (<=20).

Previous days news about CBOE (VIX)

  • Will CBOE (cboe) beat estimates again in its next earnings report?. According to Zacks on Monday, 10 April, "For the last reported quarter, CBOE came out with earnings of $1.80 per share versus the Zacks Consensus Estimate of $1.77 per share, representing a surprise of 1.69%. "

News about

  • According to FXStreet on Monday, 10 April, "Amid these plays, S&P 500 Futures print mild losses around 4,132 while snapping a two-day uptrend whereas the US 10-year and two-year Treasury bond yields remain pressured near 3.37% and 3.95% respectively. "
  • According to FXStreet on Monday, 10 April, "While portraying the mood, S&P 500 Futures print mild losses around 4,132 while snapping a two-day uptrend whereas the US 10-year and two-year Treasury bond yields remain pressured near 3.37% and 3.95% respectively. "
  • According to MarketWatch on Monday, 10 April, "Scots Miracle-Gro stock is up 47% in 2023, compared to a 6.9% increase by the S&P 500 ."
  • According to MarketWatch on Monday, 10 April, "Tesla's stock has soared 50.2% to date in 2023 through Friday, while the S&P 500 has gained 6.9%."

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com